Gerald Elfenbein

Title: Gerald Elfenbein: Innovator in Immunotherapy

Introduction

Gerald Elfenbein is a notable inventor based in Franklin, MA (US). He has made significant contributions to the field of immunotherapy, particularly through his innovative patent related to the arming of activated T cells.

Latest Patents

Gerald Elfenbein holds a patent for "In situ immunization," which focuses on the arming of activated T cells (ATC) with bispecific antibodies (BiAbs). This approach addresses major barriers in adoptive immunotherapy by leveraging the targeting specificity of monoclonal antibodies alongside the cytotoxic capabilities of T cells to effectively lyse tumors. The technology enhances the effectiveness of T cells, making them antigen-specific cytotoxic T lymphocytes (CTLs). This innovation allows for multiple tumor-killing actions without the need for rearming, while also enabling the secretion of tumoricidal cytokines and chemokines. The persistence of these armed ATCs in patients and animal models demonstrates their long-term survival capabilities, which is crucial for developing tumor-specific immune responses.

Career Highlights

Gerald Elfenbein is affiliated with Roger Williams Medical Center, where he continues to advance research in immunotherapy. His work has been instrumental in exploring the potential of armed ATCs as a cytotoxic 'drug' that can kill multiple times, divide after killing, and persist in the host for extended periods.

Collaborations

One of his notable collaborators is Lawrence G Lum, who has worked alongside Elfenbein in the field of immunotherapy.

Conclusion

Gerald Elfenbein's innovative work in immunotherapy, particularly through his patent on armed T cells, showcases his commitment to advancing cancer treatment. His contributions have the potential to significantly impact the effectiveness of adoptive immunotherapy in cancer patients.